Autopsy report · NCT02044510

Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients

“Slow recruitment and small observed effect size”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 3 years 7 months before it stopped.
• 32 participants enrolled.
• Results were posted on the registry 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2, Phase 3

Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Sponsor type

University, hospital or other

Conditions

Urinary Bladder, Neurogenic

Interventions

Mirabegron; Placebo

Participants

32

Sites

5

Countries

Canada

Trials that died the same way

• Serum-derived Bovine Immunoglobulin Effect on Mucositis
  “Recruitment slower than anticipated” (77% match in meaning)
• IU Health Krannert Personalized Medicine Study
  “Slower than anticipated recruitment” (75% match in meaning)
• Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns
  “Much slower recruitment than anticipated” (75% match in meaning)
• Efficacy of Prednisone In the Treatment of Ocular Myasthenia
  “Slow recruitment rate” (75% match in meaning)
• Efficacy and Safety Of Spil's Estradiol Vaginal Tablet
  “Slow recruitment” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.